SCHEMBL6174274

SCHEMBL6174274

CC(c1ccnc(NC(=O)c2ccc(Cl)cc2)c1)C1NC(=O)N(c2ccc(OC(F)(F)F)cc2)C1=O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GCGR P47871 5/20 0.42
F10 P00742 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
LIPE Q05469 1/20 0.39
CBLB Q13191 3/20 0.39
SLC5A1 P13866 2/20 0.39
TRPV1 Q8NER1 1/20 0.37
GIPR P48546 1/20 0.37
ABL1 P00519 1/20 0.37
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDE2A O00408 1/20 0.36
SCN8A Q9UQD0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6175302 0.92 GRM5 (0.45) LIPECBLBSLC5A1ABL1
SCHEMBL6177007 0.88 TDP1 (0.42) LIPECBLBSLC5A1PDE2A
SCHEMBL6175275 0.87 IGF1R (0.41) NPC1RAB9ACBLBTRPV1
SCHEMBL6172184 0.86 NPC1 (0.39) NPC1RAB9ACBLBMEN1KMT2A
SCHEMBL6173626 0.86 SLC5A1 (0.37) CBLBSLC5A1ABL1PDE2A
SCHEMBL6177220 0.85 LMNA (0.40) LIPESLC5A1TRPV1PDE2A
SCHEMBL6172737 0.85 MAPK1 (0.37) CBLBSLC5A1PDE2A
SCHEMBL6172084 0.84 LMNA (0.40) SLC5A1PDE2A
SCHEMBL6177704 0.84 KDR (0.42) SLC5A1
SCHEMBL6171770 0.84 LMNA (0.43) CBLBSLC5A1PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1599464-A2 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-11-30 EP disclosed
WO-2004070050-A2 CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-08-19 WO disclosed